Skip to content

Study · In vitro (cells) · 2026

2 results

Integrative In Silico and In Vitro Evaluation of Vialox and Leuphasyl Pentapeptides for Antiaging Applications.

Akhan D, Bicak B, Kurtur OB, Budama-Kilinc Y, Gunduz SK

Chemistry & biodiversity1 May 2026

PMID42116636 (opens in a new tab)PMCIDPMC13380999 (opens in a new tab)DOI10.1002/cbdv.202502546 (opens in a new tab)PepBankPUB-42116636
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Safety outcome

    In HaCaT cells, Leuphasyl showed no cytotoxicity at concentrations up to 1 mg/mL.

    In plain wordsIn cells, Leuphasyl showed no toxicity at concentrations up to 1 mg/mL.

    Peptide
    Pentapeptide-18
    Outcome
    No significant changeHaCaT cytotoxicity
    Study

    humann: not reported in source

    HaCaT cells
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    up to 1 mg/mLAs given in this study (human).

    Source sentences

    Summary
    Furthermore, both peptides showed no cytotoxicity on HaCaT cell line at concentrations up to 1 mg/mL.

Studies that did not test the peptide alone1

In this study, Pentapeptide-18 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pentapeptide-18.

  1. 02Computer modelNot a test of Pentapeptide-18 aloneIn silicoMechanism

    In computational models, Leuphasyl showed stronger interactions with MMP-13.

    In plain wordsIn computer models, Leuphasyl showed stronger interactions with MMP-13.

    Peptide
    Pentapeptide-18
    Outcome
    Direction not reportedMMP-13 interactions
    Study

    n: not reported in source

    Computational models
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Docking and molecular dynamics studies revealed that Leuphasyl showed stronger interactions with MMP-13, while Vialox preferentially targeted SIRT-1, underscoring their potential to modulate aging-related pathways.

    In this study, Pentapeptide-18 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pentapeptide-18.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.